Literature DB >> 31472914

Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.

Saeed Sadeghi1, Anthony Bejjani2, Richard S Finn3.   

Abstract

In the past decade, there has been significant progress in the treatment of primary liver cancer. There has been increasing knowledge of the molecular alterations occurring in these tumors, which is now being translated into patient care. Ongoing clinical trials will further advance the therapeutic options available to patients, including the introduction of molecular targeted therapeutics and immunotherapy approaches. Critical to the success of these new drugs, is the appropriate use of them in the clinic to maximize efficacy and limit toxicity.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; HCC; Hepatocellular carcinoma; Immunotherapy; Liver cancer; Systemic treatment; Targeted therapy

Mesh:

Substances:

Year:  2019        PMID: 31472914     DOI: 10.1016/j.soc.2019.06.015

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  3 in total

1.  The Effect of 5A nursing intervention on living quality and self-care efficacy of patients undergoing chemotherapy after hepatocellular carcinoma surgery.

Authors:  Xuejuan Zhang; Min Lai; Donghan Wu; Pidan Luo; Shuixi Fu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells.

Authors:  Yihe Yan; Leting Zheng; Qiang Du; Xiao Cui; Kun Dong; Yarong Guo; David A Geller
Journal:  Br J Cancer       Date:  2021-03-26       Impact factor: 7.640

3.  [Proteomic analysis of serum and serum exosomes, and their application in intrahepatic cholangiocarcinoma].

Authors:  Kaige Yang; Weiwei Wang; Yan Wang; Chao Yan
Journal:  Se Pu       Date:  2021-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.